IL292903B2 - Immunoglobulin derivatives for detecting amyloid deposits - Google Patents
Immunoglobulin derivatives for detecting amyloid depositsInfo
- Publication number
- IL292903B2 IL292903B2 IL292903A IL29290322A IL292903B2 IL 292903 B2 IL292903 B2 IL 292903B2 IL 292903 A IL292903 A IL 292903A IL 29290322 A IL29290322 A IL 29290322A IL 292903 B2 IL292903 B2 IL 292903B2
- Authority
- IL
- Israel
- Prior art keywords
- amino acid
- seq
- acid sequence
- set forth
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962936002P | 2019-11-15 | 2019-11-15 | |
| US202063074912P | 2020-09-04 | 2020-09-04 | |
| PCT/US2020/060596 WO2021097360A1 (en) | 2019-11-15 | 2020-11-13 | Modified immunoglobulins for targeting amyloid deposits |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL292903A IL292903A (en) | 2022-07-01 |
| IL292903B1 IL292903B1 (en) | 2025-12-01 |
| IL292903B2 true IL292903B2 (en) | 2026-04-01 |
Family
ID=75912899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292903A IL292903B2 (en) | 2019-11-15 | 2020-11-13 | Immunoglobulin derivatives for detecting amyloid deposits |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20220411489A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4058479A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7722990B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220113950A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115298214A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020385183A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022009273A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3158206A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292903B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005850A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021097360A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021097360A1 (en) | 2019-11-15 | 2021-05-20 | University Of Tennessee Research Foundation | Modified immunoglobulins for targeting amyloid deposits |
| US20240003912A1 (en) * | 2020-12-04 | 2024-01-04 | University Of Tennessee Research Foundation | Method for diagnosing amyloid diseases |
| US20240216556A1 (en) * | 2021-05-05 | 2024-07-04 | University Of Tennessee Research Foundation | Peptide-fc fusions for treating amyloid disorders |
| WO2022246433A1 (en) | 2021-05-18 | 2022-11-24 | University Of Tennessee Research Foundation | Antibody-peptide fusion proteins for treating amyloid disorders |
| WO2023043658A2 (en) * | 2021-09-14 | 2023-03-23 | Caelum Biosciences | Method of treating multiple myeloma |
| WO2023086989A1 (en) * | 2021-11-12 | 2023-05-19 | Adrx, Inc. | Transthyretin (ttr) monomer binding antibodies |
| WO2023220234A1 (en) * | 2022-05-11 | 2023-11-16 | Alexion Pharmaceuticals, Inc. | High sensitivity biotinylated peptide binding elisa assay |
| US20260070962A1 (en) * | 2022-09-02 | 2026-03-12 | University Of Tennessee Research Foundation | Chimeric antigen receptors for removal of amyloid |
| KR20260066110A (ko) | 2023-09-07 | 2026-05-12 | 유니버시티 오브 테네시 리서치 파운데이션 | 아밀로이드 질환을 진단하는 방법 |
| WO2025212955A1 (en) | 2024-04-05 | 2025-10-09 | University Of Tennessee Research Foundation | Method for diagnosing amyloid diseases |
| WO2026055521A1 (en) * | 2024-09-06 | 2026-03-12 | University Of Tennessee Research Foundation | Antibody-peptide fusion proteins for treating amyloid disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016032949A1 (en) * | 2014-08-26 | 2016-03-03 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| JPH09506262A (ja) * | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| ES2345746T3 (es) * | 1998-05-21 | 2010-09-30 | University Of Tennessee Research Foundation | Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-cd74 항체 및 그 이용방법 |
| CN101415724B (zh) | 2003-06-30 | 2015-12-02 | 特拉维夫大学未来科技开发有限公司 | 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法 |
| ATE439443T1 (de) | 2005-06-17 | 2009-08-15 | Ca Nat Research Council | NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON |
| CA2669412A1 (en) * | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| WO2009086539A2 (en) * | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
| US10076570B2 (en) | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
| WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
| US20140079691A1 (en) | 2012-09-20 | 2014-03-20 | Anaptysbio, Inc. | Thermostable antibody framework regions |
| US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
| JP7449092B2 (ja) | 2017-01-30 | 2024-03-13 | ナショナル リサーチ カウンシル オブ カナダ | 血液脳関門移動化合物及びその使用 |
| KR102607629B1 (ko) | 2017-06-29 | 2023-12-01 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 아밀로이드 침착 질환의 치료를 위한 키메라 항체 |
| US11382974B2 (en) | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
| US12018069B2 (en) | 2018-06-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
| WO2021097360A1 (en) | 2019-11-15 | 2021-05-20 | University Of Tennessee Research Foundation | Modified immunoglobulins for targeting amyloid deposits |
| WO2022246433A1 (en) | 2021-05-18 | 2022-11-24 | University Of Tennessee Research Foundation | Antibody-peptide fusion proteins for treating amyloid disorders |
-
2020
- 2020-11-13 WO PCT/US2020/060596 patent/WO2021097360A1/en not_active Ceased
- 2020-11-13 US US17/776,827 patent/US20220411489A1/en not_active Abandoned
- 2020-11-13 MX MX2022005850A patent/MX2022005850A/es unknown
- 2020-11-13 EP EP20887541.9A patent/EP4058479A4/en active Pending
- 2020-11-13 JP JP2022528305A patent/JP7722990B2/ja active Active
- 2020-11-13 KR KR1020227019864A patent/KR20220113950A/ko active Pending
- 2020-11-13 BR BR112022009273A patent/BR112022009273A2/pt unknown
- 2020-11-13 AU AU2020385183A patent/AU2020385183A1/en active Pending
- 2020-11-13 CA CA3158206A patent/CA3158206A1/en active Pending
- 2020-11-13 CN CN202080092570.1A patent/CN115298214A/zh active Pending
- 2020-11-13 IL IL292903A patent/IL292903B2/en unknown
-
2023
- 2023-03-09 US US18/181,489 patent/US12030934B2/en active Active
-
2024
- 2024-05-09 US US18/660,156 patent/US12157765B2/en active Active
- 2024-05-09 US US18/660,162 patent/US12264195B2/en active Active
-
2025
- 2025-02-12 US US19/052,001 patent/US20250368729A1/en active Pending
- 2025-06-20 JP JP2025104401A patent/JP7894099B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016032949A1 (en) * | 2014-08-26 | 2016-03-03 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
Also Published As
| Publication number | Publication date |
|---|---|
| IL292903A (en) | 2022-07-01 |
| EP4058479A1 (en) | 2022-09-21 |
| US20220411489A1 (en) | 2022-12-29 |
| KR20220113950A (ko) | 2022-08-17 |
| WO2021097360A1 (en) | 2021-05-20 |
| AU2020385183A1 (en) | 2022-05-26 |
| EP4058479A4 (en) | 2024-02-28 |
| US20250368729A1 (en) | 2025-12-04 |
| JP2025134876A (ja) | 2025-09-17 |
| IL292903B1 (en) | 2025-12-01 |
| JP2023502968A (ja) | 2023-01-26 |
| MX2022005850A (es) | 2022-08-15 |
| JP7894099B2 (ja) | 2026-07-23 |
| US12157765B2 (en) | 2024-12-03 |
| CA3158206A1 (en) | 2021-05-20 |
| BR112022009273A2 (pt) | 2022-10-04 |
| US20240294621A1 (en) | 2024-09-05 |
| JP7722990B2 (ja) | 2025-08-13 |
| US20240294620A1 (en) | 2024-09-05 |
| US12264195B2 (en) | 2025-04-01 |
| US20230265178A1 (en) | 2023-08-24 |
| CN115298214A (zh) | 2022-11-04 |
| US12030934B2 (en) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4058479A4 (en) | MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS | |
| IL286849A (en) | compounds targeting prmt5 | |
| IL277272A (en) | Rimgepent for CGRP-related disorders | |
| GB2577915B (en) | Path planning | |
| IL290253A (en) | Glycovariants of igm | |
| GB201913258D0 (en) | Antigen-binding domain | |
| ZAA201801270S (en) | Straight track design | |
| HUE064256T2 (hu) | Kollimátor | |
| EP3923306A4 (en) | COIL COMPONENT | |
| GB2581174B (en) | Antibodies against hEPCR | |
| GB201803010D0 (en) | Neurodegenerative disorders | |
| ZA202005320B (en) | Anti cd6 antibodies for treating severe asthma | |
| GB201919019D0 (en) | Antigen-binding domain | |
| IL286744A (en) | Anti fgf23 antibody | |
| NO20190133A1 (en) | Fremgangsmåte for inspeksjon av rør | |
| IL280424A (en) | Methods for treating neurodegenerative disorders | |
| HK40078607A (en) | Modified immunoglobulins for targeting amyloid deposits | |
| IL289018A (en) | Methods for treating neurodegenerative disorders | |
| IL282030A (en) | Antibodies to EPN1 | |
| IL269414A (en) | Rapar for safetyin taneis | |
| GB201915787D0 (en) | St | |
| GB201915701D0 (en) | St | |
| GB201915629D0 (en) | St | |
| GB201905370D0 (en) | Elastate inhibition | |
| GB2585898B (en) | Centraliser |